Oscar Health (OSCR) EBITDA (2020 - 2026)

Oscar Health's EBITDA history runs 7 years deep, the most recent figure standing at $60.6 million for Q1 2026.

• Quarterly EBITDA fell 79.6% year-over-year to $60.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$165.9 million (down 136.25% YoY) and the FY2025 annual result came in at -$396.4 million, down 313.41% from the prior year.
• EBITDA was $60.6 million for Q1 2026 at Oscar Health, up from -$333.7 million in the prior quarter.
• Across five years, EBITDA topped out at $297.1 million in Q1 2025 and bottomed at -$598.9 million in Q4 2022.
• A 5-year average of -$40.5 million and a median of $2.4 million in 2022 frame the typical range for EBITDA.
• Annual changes were most pronounced in 2022 — EBITDA plunged 6255.9% — and 2024, when it jumped 1138.63%.
• Oscar Health's EBITDA stood at -$598.9 million in 2022, then soared by 75.71% to -$145.5 million in 2023, then surged by 129.16% to $42.4 million in 2024, then tumbled by 886.77% to -$333.7 million in 2025, then jumped by 118.16% to $60.6 million in 2026.
• Business Quant data shows OSCR's EBITDA at $60.6 million in Q1 2026, -$333.7 million in Q4 2025, and $53.2 million in Q3 2025.